Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.40B
Last updated: Nov 17, 2026 at 4:40 PM ET
Royalty Pharma Plc (RPRX) Stock Chart
Royalty Pharma Plc (RPRX) has a latest price of $68.68 on Nov 17, 2026, 2.1% below its 52-week high of $70.13. Its price rose 77.1% over the past 12 months. The month-end price rose 69.9% over the 5 years through Oct 2026, a compound annual rate of 11.2%.
Price Chart
From Jun 2020 to Oct 2026, its highest month-end close was $67.18 in Oct 2026 and its lowest $25.51 in Dec 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RPRX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RPRX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 11.6%, and over 6 months it rose 31.6%. The month-end price rose 150.0% over the 3 years through Oct 2026, a compound annual rate of 35.7%.
| Period | Change |
|---|---|
| 1 month | +14.3% |
| 3 months | +11.6% |
| 6 months | +31.6% |
| 12 months | +77.1% |
| 12 months, with dividends | +79.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +150.0% | +35.7% |
| 5 years | +69.9% | +11.2% |
Price by Year
Its best calendar year was 2025, when the price rose 51.5%, and its weakest was 2023, when it fell 28.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $67.18 | +73.9% |
| 2025 | $38.64 | +51.5% |
| 2024 | $25.51 | -9.2% |
| 2023 | $28.09 | -28.9% |
| 2022 | $39.52 | -0.8% |
| 2021 | $39.85 | -20.4% |
Trading Range
The price is 11.5% above its 50-day average of $61.57 and 25.8% above its 200-day average of $54.60.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $68.68 | |
| 52-week high | $70.13 | -2.1% |
| 52-week low | $36.68 | +87.2% |
| 50-day average | $61.57 | +11.5% |
| 200-day average | $54.60 | +25.8% |
Price Risk
Over 3 years, its largest fall from a peak was 20.7%.
| Measure | Value |
|---|---|
| 1-year beta | 0.24 |
| Largest fall, 1 year | -12.1% |
| Largest fall, 3 years | -20.7% |
Valuation
Royalty Pharma Plc traded at 8.0x earnings at the end of 2025, against a 5-year median of 8.2x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RPRX
What is RPRX's 1-year price change?
Royalty Pharma Plc's price rose 77.1% over the past 12 months. With dividends included, the 12-month total return was 79.5%.
What is RPRX's 5-year price change?
Royalty Pharma Plc's month-end price rose 69.9% over the 5 years through Oct 2026, a compound annual rate of 11.2%. These figures leave out dividends.
What is RPRX's 52-week high and low?
Royalty Pharma Plc's 52-week high is $70.13 and its 52-week low is $36.68. Its latest price of $68.68 on Nov 17, 2026 is 2.1% below the high.
What is RPRX's beta?
Royalty Pharma Plc's 1-year beta against the S&P 500 is 0.24, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 12.1%.
Is the RPRX chart free?
Yes. Advanced Charting for RPRX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RPRX pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors